Table 1.

Effects of sorafenib, AZD6244, and sorafenib/AZD6244 on body weight at sacrifice, tumor burden, microvessel density, cell proliferation, and apoptosis of two gastric cancer xenografts

Lines of xenograftsTreatmentsBody weight at sacrifice (g)Tumor weight (mg)% T/CMicrovessel* densityKi-67 index (%)Cleaved PARP (%)
GC-28-1107Vehicle21.4 ± 0.651160 ± 102a10012.4 ± 2a57 ± 4.5a1.5 ± 0.3a
Sorafenib20.1 ± 0.55454 ± 49b394 ± 1b18 ± 2.5b12.2 ± 2b
AZD624420.5 ± 0.4880 ± 85a75.811 ± 2.5a47 ± 4a7 ± 1.5b
Sorafenib + AZD624420.1 ± 0.7207 ± 22.5c17.82 ± 0.5c8 ± 1.5c28 ± 3c
GC-27-0208Vehicle21.8 ± 0.451185 ± 73.5a10011.8 ± 2.5a60.8 ± 4.5a1.3 ± 0.4a
Sorafenib20.3 ± 0.5385 ± 29b32.45.3 ± 1.5b21.9 ± 3b11.9 ± 1.5b
AZD624420.2 ± 0.4980 ± 77a82.710.1 ± 2a45 ± 4a8.7 ± 1.5b
Sorafenib + AZD624419.9 ± 0.45142 ± 26.5c123.2 ± 1b8 ± 2c27 ± 2.5c

NOTE: Differences in body weight and tumor weight at sacrifice, Ki-67 index, and percentage of cleaved PARP–positive cells (mean ± SE) among treatment groups were analyzed by Student's t test. Treatments with different letters are significantly different from one another (P < 0.05). Efficacy of sorafenib, AZD6244, and sorafenib/AZD6244 was determined by % T/C, wherein T and C are the mean weights (mg) of drug-treated and vehicle-treated tumors on day 21 during the treatment, respectively. Experiments were repeated at least twice with similar results.

  • *Mean microvessel density of 10 random 0.159 mm2 fields. Original magnification, ×200.